Interaction of CD147 and Human Epididymis Protein 4 Promotes Invasion and Metastasis of Ovarian Cancer

Overview

Journal J Cancer

Specialty Oncology

Date 2022 Jan 10

PMID 35003362

Authors

Lingling Gao

Xin Nie

Rui Gou

Yue Qi

Juanjuan Liu

Bei Lin

Affiliations

Soon will be listed here.

Abstract

Ovarian cancer is one of the most common malignant tumors in female reproductive system. The expression of CD147 and human epididymis protein 4 (HE4) are both upregulated and associated with malignant progression in ovarian cancer. However, the important role of interaction between CD147 and HE4 in the invasion and metastasis of ovarian cancer remains unclear. The co-expression and co-localization of CD147 and HE4 in cells and tissues of ovarian cancer were detected by co-immunoprecipitation, immunohistochemistry and immunocytochemistry, double-labeling immunofluorescence method. The interaction between CD147 and annexin A2 (ANXA2) was also investigated. Furthermore, we detect the regulatory relationship between CD147 and HE4 by Western blot. Transwell assay and scratch test were conducted to explore the effect of CD147-HE4 interaction on migration and invasion of ovarian cancer. The protein CD147 and HE4 were co-immunoprecipitated and co-located in the cytoplasm and membrane of ovarian cancer tissues and cells. Both of two proteins were highly expressed and positively associated with advanced FIGO stages, poor differentiation degree and poor prognosis of ovarian cancer, and HE4 was confirmed as an independent risk factor for CD147 in ovarian cancer tissues. What's more, AXNA2 was also identified as a CD147 interacting protein in ovarian cancer. It is further confirmed that interaction between CD147 and HE4 can affect the invasion and metastasis of ovarian cancer. This study demonstrated that HE4 and ANXA2 were both CD147 interacting proteins, the expression of CD147 and HE4 can affect each other, and HE4 could promote the invasion and metastasis of ovarian cancer by regulating the expression of CD147, which may provide novel thought for early diagnosis and therapeutic target of ovarian cancer.

Citing Articles

OIP5-AS1/CD147/TRPM7 axis promotes gastric cancer metastasis by regulating apoptosis related PI3K-Akt signaling.

Chen J, Wang W, Zhang Y, Wang C, Wang W, Zheng A Front Oncol. 2023; 13:1221445.

PMID: 38156103 PMC: 10753821. DOI: 10.3389/fonc.2023.1221445.

Value of human epididymis secretory protein 4 in differentiating malignant from benign pleural effusion: an analysis of two cohorts.

Yang Q, Niu Y, Wen J, Yang D, Han Y, Wen X Ther Adv Respir Dis. 2023; 17:17534666231216566.

PMID: 38084849 PMC: 10722922. DOI: 10.1177/17534666231216566.

Expression patterns of cluster of differentiation 147 impact the prognosis of hepatocellular carcinoma.

Xu Y, He H, Wu P, Li W World J Gastrointest Oncol. 2023; 15(8):1412-1423.

PMID: 37663949 PMC: 10473926. DOI: 10.4251/wjgo.v15.i8.1412.

Recent Insight about HE4 Role in Ovarian Cancer Oncogenesis.

Anastasi E, Farina A, Granato T, Colaiacovo F, Pucci B, Tartaglione S Int J Mol Sci. 2023; 24(13).

PMID: 37445657 PMC: 10341457. DOI: 10.3390/ijms241310479.

CD147 and cyclophilin A: a promising potential targeted therapy for COVID-19 and associated cancer progression and chemo-resistance.

Bakhtiyari M, Haji Aghasi A, Banihashemi S, Abbassioun A, Tavakol C, Zalpoor H Infect Agent Cancer. 2023; 18(1):20.

PMID: 37016434 PMC: 10072013. DOI: 10.1186/s13027-023-00501-2.

References

Fan X, He D, Sheng C, Wang B, Wang L, Wu X . Therapeutic anti-CD147 antibody sensitizes cells to chemoradiotherapy targeting pancreatic cancer stem cells. Am J Transl Res. 2019; 11(6):3543-3554. PMC: 6614658. View

Huang Y, Jiang J, Dou K, Chen Z . HAb18G/CD147 enhances the secretion of matrix metalloproteinases (MMP) via cGMP/NO-sensitive capacitative calcium entry (CCE) and accordingly attenuates adhesion ability of fibroblasts. Eur J Cell Biol. 2005; 84(1):59-73. DOI: 10.1016/j.ejcb.2004.09.003. View

Moore R, Hill E, Horan T, Yano N, Kim K, MacLaughlan S . HE4 (WFDC2) gene overexpression promotes ovarian tumor growth. Sci Rep. 2014; 4:3574. PMC: 3880958. DOI: 10.1038/srep03574. View

Lu M, Ju S, Shen X, Wang X, Jing R, Yang C . Combined detection of plasma miR-127-3p and HE4 improves the diagnostic efficacy of breast cancer. Cancer Biomark. 2016; 18(2):143-148. DOI: 10.3233/CBM-160024. View

Suh D, Kim M, Lee K, Eom K, Kjeldsen M, Mirza M . Major clinical research advances in gynecologic cancer in 2017. J Gynecol Oncol. 2018; 29(2):e31. PMC: 5823987. DOI: 10.3802/jgo.2018.29.e31. View

Kong X, Chang X, Cheng H, Ma R, Ye X, Cui H . Human epididymis protein 4 inhibits proliferation of human ovarian cancer cells via the mitogen-activated protein kinase and phosphoinositide 3-kinase/AKT pathways. Int J Gynecol Cancer. 2014; 24(3):427-36. DOI: 10.1097/IGC.0000000000000078. View

Moore R, Brown A, Miller M, Skates S, Allard W, Verch T . The use of multiple novel tumor biomarkers for the detection of ovarian carcinoma in patients with a pelvic mass. Gynecol Oncol. 2007; 108(2):402-8. DOI: 10.1016/j.ygyno.2007.10.017. View

Yang J, ONeill P, Jin W, Foty R, Medina D, Xu Z . Extracellular matrix metalloproteinase inducer (CD147) confers resistance of breast cancer cells to Anoikis through inhibition of Bim. J Biol Chem. 2006; 281(14):9719-27. DOI: 10.1074/jbc.M508421200. View

Cui J, Huang W, Wu B, Jin J, Jing L, Shi W . N-glycosylation by N-acetylglucosaminyltransferase V enhances the interaction of CD147/basigin with integrin β1 and promotes HCC metastasis. J Pathol. 2018; 245(1):41-52. PMC: 5947728. DOI: 10.1002/path.5054. View

10.

Fossum S, Mallett S, Barclay A . The MRC OX-47 antigen is a member of the immunoglobulin superfamily with an unusual transmembrane sequence. Eur J Immunol. 1991; 21(3):671-9. DOI: 10.1002/eji.1830210320. View

11.

Gao J, Hu Z, Liu J, Liu D, Wang Y, Cai M . Expression of CD147 and Lewis y antigen in ovarian cancer and their relationship to drug resistance. Med Oncol. 2014; 31(5):920. DOI: 10.1007/s12032-014-0920-9. View

12.

Zhuang H, Tan M, Liu J, Hu Z, Liu D, Gao J . Human epididymis protein 4 in association with Annexin II promotes invasion and metastasis of ovarian cancer cells. Mol Cancer. 2014; 13:243. PMC: 4232681. DOI: 10.1186/1476-4598-13-243. View

13.

Toole B . Emmprin (CD147), a cell surface regulator of matrix metalloproteinase production and function. Curr Top Dev Biol. 2003; 54:371-89. DOI: 10.1016/s0070-2153(03)54015-7. View

14.

Ke X, Chen Y, Wang P, Xing J, Chen Z . Upregulation of CD147 protects hepatocellular carcinoma cell from apoptosis through glycolytic switch via HIF-1 and MCT-4 under hypoxia. Hepatol Int. 2015; 8(3):405-14. DOI: 10.1007/s12072-014-9536-6. View

15.

Ke X, Fei F, Chen Y, Xu L, Zhang Z, Huang Q . Hypoxia upregulates CD147 through a combined effect of HIF-1α and Sp1 to promote glycolysis and tumor progression in epithelial solid tumors. Carcinogenesis. 2012; 33(8):1598-607. PMC: 6276922. DOI: 10.1093/carcin/bgs196. View

16.

Deng L, Gao Y, Li X, Cai M, Wang H, Zhuang H . Expression and clinical significance of annexin A2 and human epididymis protein 4 in endometrial carcinoma. J Exp Clin Cancer Res. 2015; 34:96. PMC: 4567805. DOI: 10.1186/s13046-015-0208-8. View

17.

Dai L, Bratoeva M, Toole B, Qin Z, Parsons C . KSHV activation of VEGF secretion and invasion for endothelial cells is mediated through viral upregulation of emmprin-induced signal transduction. Int J Cancer. 2011; 131(4):834-43. PMC: 3518925. DOI: 10.1002/ijc.26428. View

18.

Long T, Su J, Tang W, Luo Z, Liu S, Liu Z . A novel interaction between calcium-modulating cyclophilin ligand and Basigin regulates calcium signaling and matrix metalloproteinase activities in human melanoma cells. Cancer Lett. 2013; 339(1):93-101. DOI: 10.1016/j.canlet.2013.07.019. View

19.

Hellstrom I, Raycraft J, Hayden-Ledbetter M, Ledbetter J, Schummer M, McIntosh M . The HE4 (WFDC2) protein is a biomarker for ovarian carcinoma. Cancer Res. 2003; 63(13):3695-700. View

20.

Kamei M, Yamashita S, Tokuishi K, Hashioto T, Moroga T, Suehiro S . HE4 expression can be associated with lymph node metastases and disease-free survival in breast cancer. Anticancer Res. 2010; 30(11):4779-83. View